Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
08 mars 2024 16h05 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
08 mars 2024 08h30 HE
|
Structure Therapeutics Inc.
Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in...
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
18 déc. 2023 07h30 HE
|
Structure Therapeutics Inc.
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0%...
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
14 nov. 2023 16h10 HE
|
Structure Therapeutics Inc.
Announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, demonstrating significant weight loss supporting once-daily dosing and an encouraging safety and...
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
29 sept. 2023 07h32 HE
|
Structure Therapeutics Inc.
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents...
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
29 sept. 2023 07h30 HE
|
Structure Therapeutics Inc.
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily...
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
10 août 2023 16h05 HE
|
Structure Therapeutics Inc.
Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of...
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
03 août 2023 17h32 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
07 juin 2023 08h30 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
Structure Therapeutics to Present at Jefferies Healthcare Conference 硕迪生物应邀出席杰富瑞健康医疗大会并发表专题演讲
31 mai 2023 16h30 HE
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, June 01, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...